Improved glycaemic control in obese diabetic ob/ob mice using n- terminally modified gastric inhibitory polypeptide

Journal of Endocrinology

Volumn 165, Issue 3, 2000, Pages 639-648

  O harte, F P M ^a   Mooney, M H ^a   Kelly, C M N ^a   Flatt, P R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPROTIN A; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIABETES CONTROL; DIABETES MELLITUS; DRUG ACTIVITY; DRUG EFFECT; DRUG HALF LIFE; GLUCOSE BLOOD LEVEL; GLYCATION; INSULIN RELEASE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN MODIFICATION;

EID: 0034131227     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.1650639     Document Type: Article

References (60)

1. Bailey CJ & Flatt PR 1982 Influence of genetic background and age on the expression of the obese hyperglycaemic syndrome in Aston ob/ob mice. International Journal of Obesity 6 11-21.
2. Bailey CJ & Flatt PR 1995 Development of antidiabetic drugs. In Drugs, Diet anil Disease, vol 2, Mechanistic Approaches to Diabetes, pp 279-326. Eds C Ioannides & PR Flatt. London: Ellis Horwood.
3. Bailey CJ & Flatt PR 1997 Animal syndromes of non-insulin-dependent diabetes mellitus. In Textbook of Diabetes, edn 2, pp 23.1-23.25. Eds J Pickup & G Williams. Oxford: Blackwell Scientific Publications.
4. Brown JC 1994 Enteroinsular axis. In Gut Peptides Biochemistry and Physiology, pp 765-784. Eds JH Walsh & GJ Dockray. New York: Raven Press.
5. Burcelin R, Dolci W & Thorens B 1999 Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1. Metabolism 48 252-258.
6. Burington RS 1973 (Ed.) Handbook of Mathematical Tables and Formulas. New York: McGraw-Hill.
7. Creutzfeldt W & Ebert R 1985 New developments in the incretin concept. Diabetologia 28 565-573.
8. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44 1126-1131.
9. Deacon CF, Hughes TE & Holst JJ 1998a Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide-1 in the anaesthetised pig. Diabetes 47 764-769.
10. Deacon CF, Knudsen LB, Madsen K, Wilberb FC, Jacobsen O & Hoist JJ 1998b Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 41 271-278.
11. Ebert R, Nuack M & Creutzfeldt W 1991 Effects of exogenous and endogenous gastric inhibitory polypeptide on plasma triglyceride responses in rats. Hormones and Metabolic Research 23 517-521.
12. Eckel RH, Fujimoto WJ & Brunzell JD 1978 Gastric inhibitory polypeptide enhances lipoprotein lipase activity in cultured pre-adipocytes. Diabetes 28 1141-1142.
13. Elahi D, Andersen DK, Brown JC, Debas H, Hershcopf RJ, Raizes GS, Tobin JD & Andres R 1979 Pancreatic α- and β-cell responses to GIP infusion in normal man. American Journal of Physiology 237 185-191.
14. Elahi D, Meneilly GS, Minaker KL, Rowe JW & Andersen DK 1986 Regulation of hepatic glucose production by gastric inhibitory polypeptide in man. In Proceedings of Sixth International Conference on Gastrointestinal Hormones, Vancouver, BC, p 18. Ottawa: National Research Council of Canada Research Journals.
15. Elahi D, McAloon-Dyke M, Fukagawa NK, Meneilly GS, Sclater AL, Minaker KL, Habener JF & Andersen DK 1994 The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regulatory Peptides 51 63-74.
16. Fehmann H-C, Göke R & Göke B 1995 Cell and molecular biology of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide. Endocrine Reviews 16 390-410.
17. Flatt PR & Bailey CJ 1981a Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 20 573-577.
18. Flatt PR & Bailey CJ 1981b Development of glucose intolerance and impaired insulin response to glucose in obese hyperglycaemic (ob/ob) mice. Hormone and Metabolic Research 13 556-560.
19. Flatt PR, Bailey CJ, Kwasowski P, Page T & Marks V 1984 Plasma immunoreactive gastric inhibitory polypeptide in obese hyperglycaemic (ob/ob) mice. Journal of Endocrinology 101 249-256.
20. Gefel D, Hendrick GK, Mojsov S, Habener J & Weir GC 1990 Glucagon-like peptide-I analogs: effects on insulin secretion and adenosine 3′,5′-monophosphate formation. Endocrinology 126 2164-2168.
21. 1-42 action in vitro. Regulatory Peptides 69 151-154.
22. Göke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J & Göke D 1993 Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. Journal of Biological Chemistry 268 19650-19655.
23. Grandt D, Sieburg B, Schimiczek M, Becker U, Holtmann G, Layer P, Reeve JR, Eysselein VE, Goebell H & Müeller M 1994 Is GLP-1 (9-36)amide an endogenous antagonist at GLP-1 receptors? Digestion 55 302A.
24. Hartmann H, Ebert R & Creutzfeldt W 1986 Insulin-dependent inhibition of hepatic glycogenolysis by gastric inhibitory polypeptide (GIP) in perfused rat liver. Diabetologia 29 112-114.
25. Holst JJ & Deacon CF 1998 Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for Type 2 diabetes. Diabetes 47 1663-1670.
26. Jia X, Brown JC, Ma P, Pederson RA & McIntosh CH 1995 Effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-I-(7-36) on insulin secretion. American Journal of Physiology 268 E645-E651.
27. Kieffer TJ, McIntosh CHS & Pederson RA 1995 Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136 3585-3596.
28. Komatsu R, Matsuyama T, Namba M, Watanabe N, Itoh H, Kono N & Tarui S 1989 Glucagonostatic and insulinotropic action of glucagon-like peptide 1- (7-36)-amide. Diabetes 38 902-905.
29. Kreymann B, Williams G, Ghatei MA & Bloom SR 1987 Glucagon-like peptide-1 7-36: a physiological incretin in man. Laucet 2 1300-1304.
30. McClenaghan NH, Barnett CR, Ah-Sing E, Abdel-Wahab YHA, O'Harte FPM, Yoon T-W, Swanston-Flatt SK & Flatt PR 1996 Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. Diabetes 45 1132-1140.
31. Maletti M, Carlquist M, Portha B, Kergoat M, Mutt V & Rosselin G 1986 Structural requirements for gastnc inhibitory polypeptide (GIP) receptor binding and stimulation of insulin release. Peptides 7 75-78.
32. Mentlein R, Gallwitz B & Schimdt WE 1993 Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. European Journal of Biochemistry 214 829-835.
33. Moody AJ, Damm Jorgensen K & Thim L 1981 Structure-function relationships in porcine GIP. Diabetologia 21 306.
34. Mooney MH, O'Harte FPM & Flatt PR 1998 Aminopeptidase resistant glycated glucagon-like peptide-1 (7-36)amide shows potent insulinotropic action in vivo. Diabetologia 41 (Suppl 1) A183.
35. Morgan LM 1996 The metabolic role of GIP: physiology and pathology. Biochemical Society Transactions 24 585-591.
36. Nauck M, Schmidt WE, Ebert R, Strietzel J, Cantor P, Hoffmann G & Creutzfeldt W 1989 Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8. Journal of Clinical Endocrinology and Metabolism 69 654-662.
37. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R & Creutzfeldt W 1993 Preserved incretin activity of glucagon-like peptide 1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. Journal of Clinical Investigation 91 301-307.
38. Oben J, Morgan L, Fletcher J & Marks V 1991 Effect of the entero-pancreatic hormones gastric inhibitory polypeptide and glucagon-like peptide-1 (7-36)amide on fatty acid synthesis in explants of rat adipose tissue. Journal of Endocrinology 130 267-272.
39. Oektedalen O, Opstad PK & Jorde R 1983 Increased plasma response of gastric inhibitory polypeptide to oral glucose and a liquid meal after prolonged starvation in healthy man. Digestion 26 114-123.
40. O'Harte FPM, Gray AM, Abdel-Wahab YHA & Flatt PR 1997 Effects ot non-glycated and glycated glucagon-like peptide-1 (7-36)amide on glucose metabolism in isolated mouse abdominal muscle. Peptides 18 1327-1333.
41. O'Harte FPM, Abdel-Wahab YHA, Conlon JM & Flatt PR 1998a Glycation of glucagon-like peptide-1 (7-36)amide: characterization and impaired action on rat insulin secreting cells. Diabetologia 41 1167-1193.
42. O'Harte FPM, Abdel-Wahab YHA, Conlon JM & Flatt PR 1998a Amino terminal glycation of gastric inhibitory polypeptide enhances its insulmotropic action on clonal pancreatic B-cells. Biochimica et Biophysica Acta 1425 319-327.
43. O'Harte FPM, Gray AM & Flatt PR 1998c Gastric inhibitory polypeptide and effects of glycation on glucose transport and metabolism in isolated mouse abdominal muscle. Journal of Endocrinology 156 237-243.
44. O'Harte FPM, Mooney MH & Flatt PR 1999 N-terrninally glycated gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglyceinic activity. Diabetes 48 758-765.
45. Ørskov C, Wettergren A & Holst JJ 1993 The metabolic rate and the biological effects of GLP-1 7-36 amide and GLP-1 7-37 in healthy volunteers are identical. Diabetes 42 658-661.
46. Pederson RA 1994 Gastric inhibitory polypeptide. In Gut Peptides Biochemistry and Physiology, pp 217-259. Eds JH Walsh & GJ Dockray. New York: Raven Press.
47. Pederson RA & brown JC 1976 The insulinotropic action of gastric inhibitory polypeptide in the perfused isolated rat pancreas. Endocrinology 99 780-785.
48. Pederson RA, Satkunarajah M, McIntosh CH, Scrocchi LA, Flamez D, Schuit F, Drucker DJ & Wheeler MB 1998a Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor - / - mice. Diabetes 47 1046-1052.
49. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CHS & Demuth H-U 1998b Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 47 1253-1258.
50. Ritzel U, Leohardt U, Ottleben M, Ruhmann A. Eckart K, Spiess J & Ramadori G 1998 A synthetic glucagon-like peptide-1 analogue with improved plasma stability. Journal of Endocrinology 159 93-102.
51. Schirra J, Sturm K, Leicht P, Arnold R, Goke B & Katschinski M 1998 Exendin(9-39)amide is an antagonist of glucagon-like peptide-1 (7-36)amide in humans. Journal of Clinical Investigation 101 1421-1430.
52. Schmidt WE. Siegel EG, Kummel H. Gallwitz B & Creutzfeldt W 1987 Commercially available preparations of porcine glucose-dependent insulinotropic polypeptide (GIP) contain a biologically inactive GIP-fragment and cholecystokinin-33/-39. Endocrinology 120 835-837.
53. Siegel EG, Schulze A, Schmidt WE & Creutzfeldt W 1992 Comparison of the effects of GIP and GLP-1 on insulin release from rat pancreatic islets. European Journal of Clinical Investigation 22 154-157.
54. Stevens VJ 1971 Determination of glucose by automatic analyser. Clinical Chemistry 32 9199-9201.
55. Suzuki S, Kawai K, Ohashi S, Mukai H, Murayana Y & Yamashita K 1990 Reduced insulinotropic effect of glucagon-like peptide 1-amide and GIP in isolated perfused diabetic rat pancreas. Diabetes 39 1320-1325.
56. Tseng CC, Kieffer TJ, Jarboe LA, Usdin TB & Wolfe MM 1996 Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. Journal of Clinical Investigation 98 2440-2445.
57. Villanueva-Peñacarrillo ML, Alcántara AI, Clemente F, Delgado E & Valverde I 1994 Potent glycogenic effect of GLP-1 (7-36)amide in rat skeletal muscle. Diabetologia 37 1163-1166.
58. Wahren J, Efendic S, Luft R, Hagenfeldt L, Bjorkman O & Felig P 1977 Influence of somatostatin on sphlachnic glucose metabolism in postabsorptive and 60-h fasted humans. Journal of Clinical Investigation 59 299-307.
59. Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA & Bloom SR 1995 Glucagon-like peptide-1 is a physiological incretin in rat. Journal of Clinical Investigation 95 417-421.
60. Wheeler MB, Gelling RW, McIntosh CHS, Georgiou J, Brown JC & Pederson RA 1995 Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signalling properties. Endocrinology 136 4629-4639.